AAPGV Margin dodolan resik Ascentage Pharma Group

Logo perusahaan publik Ascentage Pharma (AAPGV)

Ascentage Pharma Group (AAPGV) is scaling its oncology portfolio through global partnerships to achieve profitability. Its developments are based on the creation of small molecules against tumors, with success relying on international patent protection and clinical trials. Tracking the aggregate net profit margin on GURU.Markets, we note that the current value is -229.30, which reflects the current efficiency of the business's operating expenses.

Rentabilitas dodolan resik ascentage.com (AAPGV): kanggo periode 25.01.2025 - 19.11.2026

AAPGV (Ascentage Pharma Group Ltd): rincian analitis lan laporan miturut indikator

Analisis fundamental perusahaan:Ascentage - AAPGV
Barang unggulan Ascentage Pharma Group International

Evaluating the margin of safety for Ascentage Pharma Group (AAPGV), I focus on the efficiency of converting revenue into net income. This metric measures the share of residual income after deducting all operating and tax expenses. Analyzing the net margin allows for the separation of market noise from actual expense management discipline. The stability of this chart is supported by cost optimization through deep outsourcing of research and production. Seamless interaction with vendors minimizes production risks, maintaining margin sustainability.

Analisis perusahaan pesaing

ONC: Margin dodolan resik|Margin resik Halozyme Inc. (HALO)|Margin resik RevMed|Rentabilitas dodolan resik AAPG (Ascentage Pharma Group)|Margin dodolan resik CGON|UroGen Pharma - Rentabilitas dodolan resik|Bicara Therapeutics - Rentabilitas dodolan miturut bathi resik|Margin dodolan resik Personalis Inc PSNL|Erasca Oncology - Margin dodolan resik|Tingkat bathi resik DCTH (Delcath Corp)|YMAB: Margin dodolan resik|AURA - Margin dodolan perusahaan|CADL (Candel Therapeutics Inc.) - Margin dodolan resik|Rentabilitas dodolan resik ARAY (Accuray)|Rentabilitas dodolan miturut bathi resik SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Margin resik|Margin resik Citius Oncology, Inc. CTOR|HURA - Rentabilitas dodolan miturut bathi resik|protaratx.com - Margin dodolan resik|FATE - Margin dodolan resik|WHWK: Margin dodolan resik|TScan Therapeutics (TCRX) - Margin dodolan resik|Margin resik Champions Oncology|Margin resik XBIT|Margin dodolan resik CVM|Rentabilitas dodolan miturut bathi resik OS Therapies Inc. OSTX|Margin resik Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Margin resik|ANL - Margin resik|Margin resik verupharma.com|TPST: Margin dodolan resik|XLO - Margin dodolan perusahaan|Margin resik Renovaro|Margin dodolan resik muraloncology.com|Margin dodolan resik KAPA|Margin dodolan perusahaan OnKure Therapeutics, Inc.|Margin dodolan resik GDTC (w2.cytomed.sg)|CRIS - Rentabilitas dodolan miturut bathi resik|Apollomics - Margin dodolan resik|Tharimmune Corp (THAR) - Rentabilitas dodolan miturut bathi resik|ADVB: Margin dodolan resik|Rentabilitas dodolan miturut bathi resik Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Margin dodolan resik|Rentabilitas dodolan resik SBFM (Sunshine Biopharma)|Margin resik Xenetic Bio (XBIO)|Margin resik SLRX (Salarius Pharma)|Kitov Pharma - Rentabilitas dodolan miturut bathi resik|American Oncology Network (AONC) - Margin resik|BeiGene - Margin dodolan resik|Checkpoint Therapeutics, Inc. (CKPT) - Rentabilitas dodolan miturut bathi resik|ELEV (Elevation Oncology, Inc.) - Rentabilitas dodolan miturut bathi resik|iCAD Inc. - Tingkat bathi resik|Rentabilitas dodolan miturut bathi resik IKNA|Margin dodolan resik notablelabs.com|Rentabilitas dodolan miturut bathi resik VIRX (Viracta Therapeutics Inc.)|MOR - Margin resik|Margin resik NAYA Biosciences NAYA